Barrett's Esophagus and Cancer Risk
The correct answer is A) Esophageal adenocarcinoma - this patient with Barrett's esophagus is at significantly increased risk of developing esophageal adenocarcinoma, not squamous cell carcinoma or gastric malignancies.
The Direct Link Between Barrett's and Adenocarcinoma
Barrett's esophagus is the only known precursor lesion for esophageal adenocarcinoma (EAC) 1, 2. The most recent AGA guidelines (2025) explicitly state that "Barrett's esophagus (BE) is the only identifiable precursor lesion for EAC and characterized by replacement of squamous epithelium in the distal esophagus by metaplastic specialized columnar epithelium" 1. The NICE guidance (2024) reinforces this, stating "Barrett's oesophagus is the only known precursor to oesophageal adenocarcinoma, a cancer with very poor prognosis" 2.
Why Not the Other Options?
Esophageal squamous cell carcinoma (Option B): This is fundamentally wrong. Squamous cell carcinoma arises from normal squamous epithelium and is associated with different risk factors (smoking, alcohol, achalasia). Barrett's esophagus involves replacement of squamous epithelium with columnar epithelium - the exact opposite pathology.
Gastric adenocarcinoma and lymphoma (Options C & D): While Barrett's occurs at the gastroesophageal junction, the metaplastic columnar epithelium is esophageal tissue, not gastric. The progression pathway is specifically: Barrett's → low-grade dysplasia → high-grade dysplasia → invasive EAC 1.
No increased cancer risk (Option E): This is clearly incorrect given the extensive surveillance recommendations in all major guidelines specifically because of the cancer risk 1, 2, 3.
The Clinical Significance
The 2025 AGA guideline emphasizes that EAC has "increasing incidence and sobering mortality rates" with only a 20% 5-year survival rate 1. This is precisely why surveillance programs exist - to detect dysplasia and early EAC when endoscopic eradication therapy can be curative, avoiding the need for esophagectomy with its associated morbidity and mortality 1, 2.
The progression is stepwise and probabilistic: Barrett's → LGD → HGD → invasive EAC, which is why your 48-year-old patient needs enrollment in a surveillance program with high-definition endoscopy 1.